{"id":"NCT00950911","sponsor":"Amgen","briefTitle":"Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only","officialTitle":"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2012-02","completion":"2012-04","firstPosted":"2009-08-03","resultsPosted":"2014-02-11","lastUpdate":"2014-02-11"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Bone Metastases in Men With Hormone-Refractory Prostate Cancer","Bone Metastases in Subjects With Advanced Breast Cancer","Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"amg 162","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (ZometaÂ®) or denosumab.","primaryOutcome":{"measure":"Number of Participants Survived","timeFrame":"2 years","effectByArm":[{"arm":"Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W","deltaMin":13,"sd":null},{"arm":"Denosumab 120 mg Q4W / Denosumab 120 mg Q4W","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":17,"countries":["Czechia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":17},"commonTop":["Fatigue","Anaemia","Nausea","Back pain","Vomiting"]}}